ANZCTR search results

Surviving infants < 30 weeks' gestational age will be randomly alloacted to a developmental care package delivered in the home or to standard follow-up care over the first year of life. The major endpoint is the Mental Developmental Index on the Bayley Scales of Infant Devlopment at 2 years of age, corrected for prematurity

Drug hypersensitivity reactions mediated by T cells are increased in HIV infection and particular HLA types have been associated with reactions to the antiretroviral drugs Abacavir [HLA-B*5701] and Nevirapine [HLA-DRB1*0101]. B57 strongly predicts reactions with Abacavir probably via a direct effect of the drug on dendritic cell activation. Abacavir naïve subjects with B57 can also generate immunological response during in vitro culture suggesting a high precursor frequency for abacavir specific T cells responses. This project aims to determine how these drugs lead to hypersensitivity reactions and to define the genetic and immunological factors that can be used to predict reactions.

The purpose of the study is to compare the effectiveness of two treatment regimens in clearing the Hepatitis C Virus in patients infected with Hepatitis C genotype 1. The study aims to determine whether a higher dose of pegylated interferon given in combination with ribavirin for the first 12 weeks of therapy results in a higher rate of viral clearance and whether it is safe and tolerable.

Observations from previous studies suggest that the full action of GH requires the presence of male hormones like Testosterone (T). We will test the hypothesis that T enhances GH effect acting on the liver. We will compare the body protein production after delivering T exclusively to the liver (capsules) and to peripheral tissues (patch). The first phase (11 weeks, 6 visits) aims to find the T dose which exposes the liver to normal/physiological T levels. The second phase (16 weeks, 5 visits) will compare the effect of delivering T to the liver and to peripheral tissues.